Small Molecule Compounds for Enhanced CNS Penetration and Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current small molecule therapies for cancer have a narrow therapeutic index, cause unwanted drug toxicity, are not highly selective, and often lead to drug resistance, poor penetrance into sanctuary sites like the CNS, and result in toxic side effects.
Innovation Solution
Development of novel compounds with specific substitutions and formulations, such as those in formulas (I) and (II), which exhibit enhanced selectivity and solubility, and can be administered in combination with other agents to enhance efficacy against various cancers, including solid tumors and metastatic forms, while minimizing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Volume of moving object
If high concentrations of small molecules are administered to achieve poor penetrance into sanctuary sites, then CNS penetration is improved, but toxic side effects increase
Solution Approach 1:
The patent modifies chemical parameters of the small molecule compounds by introducing specific heteroaryl groups and substituents (R1-R8) to enhance CNS penetration through the blood-brain barrier while maintaining selective toxicity. This allows effective concentrations to be achieved in the CNS without proportionally increasing systemic toxicity.
Solution Approach 2:
The compounds are designed to achieve localized high concentration specifically in the CNS sanctuary sites while maintaining lower concentrations in peripheral tissues. The molecular structure modifications enable selective accumulation in the target compartment (CNS) without proportionally increasing exposure in non-target tissues, thereby improving the therapeutic index.
2Reliability
If small molecule therapies are used to treat cancer, then cancer cell viability is reduced, but selectivity is poor causing unwanted drug toxicity
Solution Approach 1:
The patent introduces specific heteroaryl groups (pyrimidinyl, pyridinyl, thiazolyl, oxazolyl, isoxazolyl) with distinct electronic and steric properties to enhance selective binding to cancer-specific targets. These localized molecular modifications improve target specificity while minimizing off-target effects, thereby reducing unwanted toxicity.
Solution Approach 2:
The compounds represent composite molecular structures combining multiple functional groups (heteroaryl rings, substituents R1-R8) that work synergistically to achieve both high cancer cell killing activity and improved selectivity. The composite nature of these molecules allows simultaneous optimization of efficacy and safety profiles.
3Reliability
If small molecule therapies are administered to treat cancer, then tumor growth is inhibited, but drug resistance develops over time
Solution Approach 1:
The patent systematically varies key molecular parameters including heteroaryl group type, substituent position, and molecular size to create compounds with novel mechanisms of action. This diversity in chemical structure enables targeting of alternative or complementary pathways that may bypass resistance mechanisms developed against conventional therapies.
Data Source
Figure 1
Figure 2
Figure 3~4
AI summary
Embodiments of the instant disclosure relate to novel compounds, compositions, and methods for treating health conditions. In certain embodiments, methods of treating cancers can include administering an effective amount of at least one novel compound disclosed herein to a subject having cancer. In some embodiments, methods of treating cancers can include administering a pharmaceutical composition disclosed herein to a subject, the composition including at least one of the novel compounds disclosed herein, and optionally, one additional agent.